STOCK TITAN
  1. Home
  2. News
  3. ARDX

Ardelyx Inc - ARDX STOCK NEWS

Welcome to our dedicated news page for Ardelyx (Ticker: ARDX), a resource for investors and traders seeking the latest updates and insights on Ardelyx.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ardelyx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ardelyx's position in the market.

News
Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023
Rhea-AI Summary
Ardelyx, Inc. will present positive data on IBSRELA (tenapanor) at the American College of Gastroenterology annual meeting. The data shows a quick onset of symptom relief and increased response rates with continued therapy. Tenapanor improves abdominal symptoms independent of changes in bowel movement frequency and reduces bloating. The company is sponsoring a Product Theater to discuss clinical considerations and share efficacy and safety data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.81%
Tags
none
-
News
Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
Rhea-AI Summary
Ardelyx, Inc. to hold conference call for third quarter financial results and business update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.03%
Tags
conferences earnings
-
News
Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital
Rhea-AI Summary
Ardelyx secures additional non-dilutive capital to support the launch of XPHOZAH and continued investment in IBSRELA
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.33%
Tags
none
News
FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor
Rhea-AI Summary
The U.S. FDA has approved XPHOZAH, a phosphate absorption inhibitor, for reducing serum phosphorus in adults with chronic kidney disease (CKD) on dialysis. XPHOZAH is a single tablet taken twice daily and offers a first-in-class mechanism of action.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.33%
Tags
fda approval
-
News
Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA
Rhea-AI Summary
Ardelyx announces upcoming data presentations for tenapanor for hyperphosphatemia at the American Society of Nephrology Kidney Week 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
conferences
-
News
Ardelyx Shares Preliminary Data on Use of IBSRELA® (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023
Rhea-AI Summary
Ardelyx shares data on investigational use of IBSRELA in pediatric patients at NASPGHAN Annual Meeting. IBSRELA has shown improvements in constipation and abdominal symptoms in adults with IBS-C. Safety and efficacy of IBSRELA in pediatric patients being evaluated. No serious adverse events reported in preliminary safety data. IBSRELA contraindicated in patients less than 6 years of age. Diarrhea reported as common adverse reaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
none
News
Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility
Rhea-AI Summary
Ardelyx, Inc. announces publication of long-term safety trial results for IBSRELA in the treatment of IBS-C, showing acceptable tolerability and consistent safety profile. Provides valuable data for IBSRELA as a treatment option. Diarrhea reported as the most common adverse event. Important safety information includes contraindications for pediatric patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
none
-
News
Tenapanor for Hyperphosphatemia Approved in Japan
Rhea-AI Summary
Ardelyx receives $30 million milestone payments and $5 million from Kyowa Kirin and HealthCare Royalty Partners for the approval of tenapanor in Japan for hyperphosphatemia in CKD patients on dialysis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
none
-
News
Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023
Rhea-AI Summary
Ardelyx shares encouraging data on IBSRELA at GHAPP conference, demonstrating safety and efficacy of the treatment. Patients reported reduction in abdominal symptom scores and higher treatment satisfaction. Pooled analysis shows higher proportion of patients with durable complete spontaneous bowel movement response. No significant negative impacts on stock price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.05%
Tags
none
News
Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Summary
Ardelyx CEO to present at H.C. Wainwright Conference on Sept. 11 at 12:00 p.m. ET in NYC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
conferences
Stock ARDX logo
Ardelyx Inc

Nasdaq:ARDX

ARDX Rankings

#2113 Ranked by Market Cap
#88 Ranked by Stock Gains
N/A Ranked by Dividends

ARDX Stock Data

1.56B
226.69M
1.95%
60.33%
15.05%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Fremont

About ARDX

ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.